Report

Teaser, summary, work performed and final results

Periodic Reporting for period 1 - Nano4 (Colorimetric Precision Nanodiagnostics made Fast and Affordable)

Teaser

There is a need for cost-effective molecular point of care diagnostic tools to provide better healthcare to patients and better agility to the healthcare system. Furthermore, there is the need to extend the limits of molecular diagnostics to the nanoscale.The market needs a...

Summary

There is a need for cost-effective molecular point of care diagnostic tools to provide better healthcare to patients and better agility to the healthcare system. Furthermore, there is the need to extend the limits of molecular diagnostics to the nanoscale.
The market needs a rapid and definitive answer at entry level. It needs a diagnostic that is capable of screening directly and simply hundreds of samples with low infrastructure and untrained professionals, that currently can only rely on the existing infrastructure like peripheral hospital and microscopy centres.
We have developed a nanotechnology-based solution. NANO4 is a fast and user-friendly nano-based diagnostic technology suitable for use at Point of Need. NANO4 represents a highly specific and sensitive nanotechnology for in vitro molecular diagnostics. It uses gold nanoprobes to recognize the complementary DNA/ RNA strand and yield a colour output that allows for quick decision making.
Molecular diagnosis is a multi-million Euro market. Our business objective is to make Nano4 a standard diagnostics technology present at each Point of Need and to become the global leader in nano-based molecular diagnostic technology. Easily accessible fast molecular testing is a tremendous challenge especially when reliable results are needed quickly and cost efficiently.
We defined our go-to-market roadmap for our first disruptive products: NANO4 TB for Tuberculosis, and NANO4 CML for Chronic Myeloid Leukaemia, including industrial scale-up and obtaining the CE mark.

Work performed

NANO4 Global, reached the first 12 months in line with milestones submitted. Relevant objectives completed: set-up of our industrial facility; Scale-up process of production; and Certification of NANO4 Global according to ISO 13485:2016 and 9001:2015.
Towards future commercialization, Nano4 implemented the first steps for commercial approach. An important and impactful development was under Intellectual Property associated to PCT.

Final results

According to WHO in 2017, 10 million people developed Tuberculosis. Despite all efforts to eradicate TB – like the StopTB initiative coordinated by WHO and FIND, the number of patients increased. In 2017 more than 1.3 million people with TB died.
According to those at the forefront of this epic fight, there is a tremendous need for diagnostic tools. NANO4 technology will have an impact on the diagnostics of Tuberculosis, making it fast, easy and affordable.
This project has had a fundamental impact on the development of NANO4.
In the end of the project, our Nano4 TB diagnostic product will be launched in the market and several important milestones will be accomplished: apart from technical and regulatory achievements that allow the product to reach the standards to be in the market, new patents will be submitted.

Website & more info

More info: https://nano4global.com.